You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Article Text

Article menu

Download PDFPDF

XML
Correction
Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

https://doi.org/10.1136/jitc-2019-000391corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Ascierto PA, Del Vecchio M, Mackiewicz A, et al. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. J ImmunoTher Cancer 2020;8:e000391. doi: 10.1136/jitc-2019-000391

    Since the online publication of this article, it was noticed that ‘Michele Del Vecchio’ was incorrectly spelt as ‘Michelle Del Vecchio’. This error has been corrected.